Mark Knapp

3.5k citations

24 papers · 1.2k · h-index 17

Impact in

Genetics top 10%
- Chronic Lymphocytic Leukemia Research
Molecular Biology top 10%
- PI3K/AKT/mTOR signaling in cancer
- Biochemical and Molecular Research
- Protein Structure and Dynamics

Papers in

Molecular Biology 16
- PI3K/AKT/mTOR signaling in cancer 7
- Biochemical and Molecular Research 4
- Cancer therapeutics and mechanisms 2
Organic Chemistry 4
- Quinazolinone synthesis and applications 4
- Synthesis and biological activity 2

Co-authors: Bernhard Rupp (5 shared papers)Mark L. Segall (1 shared paper)Julie Morrow (1 shared paper)Sissel Lund‐Katz (1 shared paper)Karl H. Weisgraber (1 shared paper)Michael C. Phillips (1 shared paper)Pascal Furet (4 shared papers)Joachim Blanz (3 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (5 papers)ACS Medicinal Chemistry Letters (4 papers)Protein Expression and Purification (2 papers)Biochemistry (2 papers)Proceedings of the National Academy of Sciences (2 papers)
Partner nations: United States Switzerland China

In The Last Decade

Mark Knapp

24 papers receiving 1.2k citations

Peers

Countries citing papers authored by Mark Knapp

Since Specialization

Citations

This map shows the geographic impact of Mark Knapp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Knapp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Knapp more than expected).

Fields of papers citing papers by Mark Knapp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Knapp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Knapp. The network helps show where Mark Knapp may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Knapp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Knapp Line = papers co-authored together Mark Knapp links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation Bioorganic & Medicinal Chemistry Letters ·Pascal Furet, Vito Guagnano, Robin A. Fairhurst, Patricia Imbach‐Weese, Ian C. Bruce, Mark Knapp, Christine Fritsch, Francesca Blasco, Joachim Blanz, Reiner Aichholz, Jacques Hamon, Doriano Fabbro, Giorgio Caravatti	2013	350
2	Differences in Stability among the Human Apolipoprotein E Isoforms Determined by the Amino-Terminal Domain Biochemistry ·Julie Morrow, Mark L. Segall, Sissel Lund‐Katz, Michael C. Phillips, Mark Knapp, Bernhard Rupp, Karl H. Weisgraber	2000	274
3	Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity Proceedings of the National Academy of Sciences ·Brent W. Segelke, Mark Knapp, Saloumeh Kadkhodayan, Rod Balhorn, Bernhard Rupp	2004	77
4	Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance Nature Communications ·Ala M. Shaqra, Sarah N. Zvornicanin, Qiu Yu J. Huang, G.J. Lockbaum, Mark Knapp, Laura Tandeske, David T. Bakan, Julia M. Flynn, Daniel N. Bolon, Stephanie Moquin, Dustin Dovala, Neşe Kurt Yılmaz, Celia A. Schiffer	2022	73
5	Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors ACS Medicinal Chemistry Letters ·Klemens Hoegenauer, Nicolas Soldermann, Frédéric Stauffer, Pascal Furet, Nadège Graveleau, Alexander B. Smith, Christina Hebach, Gregory J. Hollingworth, Ian Lewis, Sascha Gutmann, Gabriele Rummel, Mark Knapp, Romain M. Wolf, Joachim Blanz, Roland Feifel, Christoph Burkhart, Frédéric J. Zécri	2016	49
6	Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy in Vivo ACS Medicinal Chemistry Letters ·Ayako Honda, Edmund Harrington, Iván Cornella‐Taracido, Pascal Furet, Mark Knapp, Meir Glick, Ellen Triantafellow, William E. Dowdle, Dmitri Wiedershain, Wieslawa Maniara, Christine Moore, Peter M. Finan, Lawrence G. Hamann, Brant Firestone, Leon O. Murphy, Erin P. Keaney	2015	40
7	Structure-guided enzymology of the lipid A acyltransferase LpxM reveals a dual activity mechanism Proceedings of the National Academy of Sciences ·Dustin Dovala, Christopher M. Rath, Qijun Hu, William S. Sawyer, Steven Shia, R.A. Elling, Mark Knapp, Louis E. Metzger	2016	38
8	Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors ACS Medicinal Chemistry Letters ·Paul A. Barsanti, Robert J. Aversa, Xianming Jin, Yue Pan, Yipin Lu, R.A. Elling, Rama Jain, Mark Knapp, Jiong Lan, Xiaodong Lin, Patrick J. Rudewicz, Janet Sim, Lorena Taricani, George Thomas, Linda Xiao, Qin Yue	2014	30
9	Abstract 4498: Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials Cancer Research ·Charles F. Voliva, Sabina Pecchi, Matthew T. Burger, Tobi Nagel, Christian Schnell, Christine Fritsch, Saskia M. Brachmann, Daniel L. Menezes, Mark Knapp, Kevin Shoemaker, Marion Wiesmann, Kay Huh, Isabel Zaror, Marion Dorsch, William R. Sellers, Carlos Garcı́a-Echeverrı́a, Michel Maira	2010	29
10	Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors Journal of Molecular Biology ·Yipin Lu, Mark Knapp, Kenneth Crawford, Robert Warne, R.A. Elling, Kelly Yan, Michael Doyle, Gwynn Pardee, Li Zhang, Sylvia Ma, Mulugeta Mamo, Elizabeth Ornelas, Yue Pan, Dirksen E. Bussiere, Johanna M. Jansen, Isabel Zaror, Albert Lai, Paul A. Barsanti, Janet Sim	2017	28
11	Carboxyl-Terminal Domain of Human Apolipoprotein E: Expression, Purification, and Crystallization Protein Expression and Purification ·Michael Forstner, Clare Peters‐Libeu, Emeline Contreras-Forrest, Yvonne M. Newhouse, Mark Knapp, Bernhard Rupp, Karl H. Weisgraber	1999	25
12	Identification of Novel Small Molecule Ligands That Bind to Tetanus Toxin Chemical Research in Toxicology ·Felice C. Lightstone, Maria C. Prieto, Anup K. Singh, M.C. Piqueras, Randy M. Whittal, Mark Knapp, Rod Balhorn, Diana C. Roe	2000	25
13	Identification and structure–activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Sabina Pecchi, Paul A. Renhowe, Clarke Taylor, Susan Kaufman, Hanne Merritt, Marion Wiesmann, Kevin Shoemaker, Mark Knapp, Elizabeth Ornelas, Thomas F. Hendrickson, Wendy J. Fantl, Charles F. Voliva	2010	24
14	Cloning, Expression, and One-Step Purification of the Minimal Essential Domain of the Light Chain of Botulinum Neurotoxin Type A Protein Expression and Purification ·Saloumeh Kadkhodayan, Mark Knapp, James J. Schmidt, Sarah E. Fabes, Bernhard Rupp, Rod Balhorn	2000	23
15	Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors ACS Medicinal Chemistry Letters ·Matthew T. Burger, Mark Knapp, Allan S. Wagman, Zhi‐Jie Ni, Thomas F. Hendrickson, Gordana Atallah, Yanchen Zhang, Kelly Frazier, Joelle Verhagen, Keith Pfister, Simon S.M. Ng, Aaron Smith, Sarah Bartulis, Hanne Merrit, Marion Weismann, Xiaohua Xin, Joshua Haznedar, Charles F. Voliva, Ed Iwanowicz, Sabina Pecchi	2010	23
16	Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model Bioorganic & Medicinal Chemistry Letters ·Wooseok Han, Daniel L. Menezes, Yongjin Xu, Mark Knapp, R.A. Elling, Matthew T. Burger, Zhi‐Jie Ni, Aaron Smith, Jiong Lan, Teresa E. Williams, Joelle Verhagen, Kay Huh, Hanne Merritt, John S.D. Chan, Susan Kaufman, Charles F. Voliva, Sabina Pecchi	2016	20
17	Do Enzymes Change the Nature of Transition States? Mapping the Transition State for General Acid−Base Catalysis of a Serine Protease Biochemistry ·R. Bott, Gina Chan, Blanca Domingo, Grant Ganshaw, Constance Y. Hsia, Mark Knapp, Christopher J L Murray	2003	16
18	Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors Bioorganic & Medicinal Chemistry Letters ·Robin A. Fairhurst, Marc Gerspacher, Patricia Imbach‐Weese, Robert Mah, Giorgio Caravatti, Pascal Furet, Christine Fritsch, Christian Schnell, Joachim Blanz, Francesca Blasco, Sandrine Desrayaud, Daniel Guthy, Mark Knapp, Dorothee Arz, Jasmin Wirth, Esther Roehn-Carnemolla, Van Huy Luu	2015	15
19	Targeting Cancer: The Challenges and Successes of Structure-Based Drug Design Against the Human Purinome Current Topics in Medicinal Chemistry ·Mark Knapp, Cornelia Bellamacina, Jeremy Murray, Dirksen E. Bussiere	2006	13
20	A polyomavirus peptide binds to the capsid VP1 pore and has potent antiviral activity against BK and JC polyomaviruses eLife ·Joshua R. Kane, Susan Fong, Jacob Shaul, Alexandra Frommlet, Andreas O. Frank, Mark Knapp, Dirksen E. Bussiere, Peter Kim, Elizabeth Ornelas, Carlos Cuellar, Anastasia Hyrina, Johanna R. Abend, Charles Wartchow	2020	7

About Mark Knapp

Mark Knapp is a scholar working on Molecular Biology, Organic Chemistry, Cellular and Molecular Neuroscience, Neurology and Oncology, having authored 24 papers that have together received 1.2k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (7 papers), Quinazolinone synthesis and applications (4 papers), Biochemical and Molecular Research (4 papers), Botulinum Toxin and Related Neurological Disorders (3 papers), Hereditary Neurological Disorders (2 papers), Cancer therapeutics and mechanisms (2 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Synthesis and biological activity (2 papers). The work is most often cited by research in Genetics (127 citations), Molecular Biology (769 citations), Organic Chemistry (219 citations), Neurology (104 citations) and Pharmaceutical Science (35 citations). Mark Knapp has collaborated with scholars based in United States, Switzerland and China. Frequent co-authors include Bernhard Rupp, Mark L. Segall, Julie Morrow, Sissel Lund‐Katz, Karl H. Weisgraber, Michael C. Phillips, Pascal Furet, Joachim Blanz, Christine Fritsch and Robin A. Fairhurst. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, ACS Medicinal Chemistry Letters, Protein Expression and Purification, Biochemistry and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Mark Knapp

Impact in

Papers in i

In The Last Decade

Mark Knapp

Peers

Countries citing papers authored by Mark Knapp

Fields of papers citing papers by Mark Knapp

All Works

About Mark Knapp

Explore authors with similar magnitude of impact

Papers in